Abstract
No drug can be testified to be entirely free of undesired effects. These undesired or unintended effects of drug administration are broadly called adverse effects. When the concept of causality is factored in, the term adverse drug reaction is used. This causality assessment can be done in several ways, Naranjo scale and WHO-UMC scale being the most common ones. Pharmacovigilance is a growing domain that concerns the detection, assessment, understanding and prevention of drug-related adverse effects. On a similar line, hemovigilance is the set of activities that govern adverse effects related to transfusion chains. When the medical materials and devices are involved, it is called materiovigilance, and when cosmetic products are concerned, the cosmetovigilance comes in to play. Addictovigilance is an ill-defined category of events that cover drugs of addictive or recreational misuse. This chapter covers the broad types of vigilance (medicovigilance) and their relevance in the Indian scenario.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsBibliography
Boparai JK, Singh S (2015) Hemovigilance: a new beginning in India. Int J App Basic Med Res 5:200–202
Faber JC (2004) Haemovigilance procedure in transfusion medicine. Hematol J 5:S74–S82
Flesland O, Wiersum-Osselton JC (2016) Donor vigilance and hemovigilance. In: Tl S, McCullough J, Snyder EI, Solheim B, Strauss RJ (eds) Rossi’s principles of transfusion medicine. Wiley Blackwell, Chichester, pp 58–68
Gentile G, Jego M, Spadari M, Griffiths K, Jouanjus E, Micallef J (2018) Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network? Fund Clin Pharmacol 32:643–651
Gupta P, Janodia MD, Jagadish PC, Udupa N (2010) Medical device vigilance systems: India, US, UK, and Australia. Med Devices (Auckl) 3:67–79
Jain A, Kaur R (2012) Hemovigilance and blood safety. Asian J Transfus Sci 6(2):137–138
Jouanjus E, Gibaja V, Kahn J-P, Haramburu F, Daveluy A (2015) Signal identification in addictovigilance: the functioning of the French system. Therapie 70:113–131
Kalaiselvan V, Thota P, Singh GN (2016) Pharmacovigilance programme of India: recent developments and future perspectives. Indian J Pharmacol 48:624–628
Kalaiselvan V, Srivastava S, Singh A, Gupta SK (2018) Pharmacovigilance in India: present scenario and future challenges. Drug Saf 42:339–346
Medical device adverse event reporting form. [Online] [cited 2018 Sep 20]; Available from: URL http://ipc.nic.in/writereaddata/mainlinkFile/File528.pdf
Moretti U, Velo G (2008) Cosmetovigilance: the “beautiful” risk. Drug Saf 31:437–439
Mukherjee S, Maiti R (2016) Haemovigilance: a current update in Indian perspective. J Clin Diagn Res 10:5–9
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245
Pharmacovigilance Programme of India (PvPI). [Internet] 2017 [cited 2018 Oct 13]. Available from: http://www.ipc.gov.in/PvPI/about.html
Rani S, Singh K (2018) Materiovigilance: an emerging discipline. Int J Sci Res 7:15–16
Sarma P, Kumar H, Medhi B (2017) Cosmetovigilance in India: need of the day. Indian J Pharmacol 49(5):341–343
Tripathi KD (2013) Adverse drug effects. In: Essentials of medical pharmacology, 7th edn. Jaypee Publishers, New Delhi, pp 82–91
Tseng ZH, Hayward RM, Clark NM, Mulvanny CG, Colburn BJ, Ursell PC et al (2015) Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med 175:1342–1350
Udupa N, Ligade V (2016) Need of cosmetovigilance in India. Value Health 19(7):A836
Vigan M, Castelain F (2014) Cosmetovigilance: definition, regulation and use “in practice”. Eur J Dermatol 24(6):643–649
Zaki SA (2011) Adverse drug reaction and causality assessment scales. Lung India 28(2):152–153
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Arivazhahan, A., Kunder, S.K. (2019). Adverse Effects and Pharmacovigilance. In: Raj, G., Raveendran, R. (eds) Introduction to Basics of Pharmacology and Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-32-9779-1_11
Download citation
DOI: https://doi.org/10.1007/978-981-32-9779-1_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9778-4
Online ISBN: 978-981-32-9779-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)